This may indicate that TREM2‐stimulating therapeutic approaches could be employed in a variety of different clinical syndromes including AD, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, retinal degeneration, multiple sclerosis, and obesity‐associated metabolic syndromes. This evidence concerns the gene TREM2 and frontotemporal dementia.